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Role of heparin as a protective agent following reduction of renal mass.
To determine the mechanism by which heparin affords protection from
damage to the remnant kidney following reduction of renal mass, either
whole heparin or a low molecular weight fraction of heparin was
administered to Munich-Wistar rats which had had 90% ablation of
renal mass. The low molecular weight fraction differed from the whole
heparin in that it had greatly decreased anticoagulant activity as
measured by the United States Pharmacopoiea (USP) assay, and
increased antifactor Xa activity. The morphological alterations were
examined and various physiological features were studied. The admin-
istration of whole heparin to rats with reduction of renal mass resulted
in prolonged clotting time, reduced BP elevation, elimination of albu-
minuria, and lessening of renal damage. No such differences were
observed in the rats receiving the fraction of heparin or the control
group to which no therapy was given. The inability of the fraction of
heparin to prolong clotting time suggested that it was unable to
inactivate the serine proteases of the coagulation cascade. It is probable
that the protective effect of whole heparin in this model is due to its
ability to inhibit serine proteases such as kallikrein and components
of the coagulation cascade resulting in a beneficial alteration in gb-
merular hemodynamics, lowering of systemic BP, and anticoagulation.
Role de l'heparine comme agent protecteur après reduction de Ia masse
rénale. Afin de determiner le mécanisme par lequel l'héparine permet Ia
protection contre la destruction du rein restant aprés reduction de Ia
masse rénale, de l'héparine entière, ou une fraction de faible poids
moléculaire d'héparine ont été administrées a des rats Munich-Wistar
qui avaient eu une ablation de 90% de leur masse rCnale. La fraction de
faible poids moléculaire différait de l'héparine totale en ce qu'elle avait
une activité anticoagulante très diminuée mesurée par be dosage de
l'United States Pharmacopoiea (USP), et une augmentation de l'activité
anti-facteur Xa. Les alterations morphologiques ant été examinées, et
diffCrentes caractéristiques physiobogiques ont étd étudiCes. L'adminis-
tration d'heparine totale a des rats avec une reduction de la masse
rCnale a entrainé une augmentation du temps de coagulation, une
diminution de l'élévation de Ia pression artCrielle, une disparition de
l'albuminurie, et une diminution des lesions renales. De telles differ-
ences n'ont pas etC observées chez les rats recevant Ia fraction de
l'héparine, ni dans le groupe contrôle auquel aucune therapeutique
n'avait etC administrée. L'incapacité de La fraction d'heparine de
prolonger Ic temps de coagulation a suggéré qu'elle était incapable
d'inactiver les protCases seriques de la cascade de la coagulation. Il est
probable que l'effet protecteur de l'heparine totale dans cc modèle est
dO sa capacitC d'inhiber les protéases sériques comme la kallikréine et
les composants de Ia cascade de Ia coagulation, entrainant une alter-
ation benéfique de l'hemodynamique glomerulaire, abaissant Ia pres-
sion artCrielle systemique, et par son effet anticoagulant.
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Reduction of renal mass in the rat results in functional
hypertrophy and morphological injury of the nephrons through-
out the remnant kidney [1—5]; alterations can be detected within
1 week following severe renal ablation [4]. Progressive glomeru-
lar damage ensues with eventual glomerubosclerosis, protein-
uria, and uremia followed by death [6—9]. This deterioration of
both renal structure and function can be partially prevented
with heparin therapy [7, 10], but the mechanism by which this
protection operates is unclear.
Heparin has numerous physiological actions which may be
responsible for this beneficial effect. The neutralization of
serine proteases may provide anticoagulation and inhibition of
kallikreins [11, 12]. Further, heparin by virtue of its anionic
nature can enhance the negative electric potential of the vascu-
lar wall [10, 11]. The aim of the present experiments was to
determine which of these actions of heparin contributes to the
improvement seen in this model by using two preparations of
heparin with differing properties. One was whole heparin and
the other a low molecular weight fraction of heparin which had
decreased anticoagulant activity and increased antifactor Xa
activity compared to the whole heparin. This difference in the
clotting profile indicates an inability on the part of the fraction
of heparin to inhibit serine proteases. Both whole heparin and
the fraction of heparin were anionic. Following severe reduc-
tion of renal mass the effects of these two agents on various
physiological features were assessed, and the morphological
alterations in the different treatment groups were evaluated.
Methods
Male Munich-Wistar rats weighing between 200 to 300 g were
used. They were bred from stock supplied by Dr. Carl Gott-
schalk (University of North Carolina, Chapel Hill, North Caro-
lina). Baseline systolic BP was measured by tailcuff under light
ether anesthesia the week prior to operation. All rats used in the
study had initial systolic pressures less than 110 mm Hg. All
rats underwent right nephrectomy and infarction of approxi-
mately five-sixths of the left kidney by ligation of branches of
the renal artery to that kidney. This operation reduced renal
mass to 10% of normal. On the day following surgery a 14-day
Alzet mini-osmotic pump (Alza Corporation, Palo Alto, Califor-
nia) containing the heparin preparation was placed in a subcuta-
neous pocket over the left scapula of each rat. A PE 60
polyethylene catheter attached to the pump was inserted into
the left jugular vein. The contents of these pumps were deliv-
ered at a rate of 12 p1/day thereby maintaining constant blood
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Table 1. Characterization of heparins used in study
Experimental
Amounts administered
Molecular weight USP Anti Xa USP Anti Xa Mass heparin
group Heparin lot # daltons U/mg U/mg U/kg/day U/kg/day mg/kg/day
I Whole 15000 145 150 496 513 285
(N5195)
2 Fraction 5500 29 2000 36 2508 105
(P2658)
Table 2. Comparison of clotting time, albumin excretion, mean arterial pressure, serum creatinine, and hematocrit
Body weight ratio
final Clotting time Urine albumin Mean arterial pressure Serum creatinine
Groups initial minutes mg/24 hr mm/Hg mg/dl Hematocrit
1 226 28 4.13 3.8 0.74 1.0 125 25 1.24 0.22 35 5
233 33 (6) (7) (7) (7) (6)
(7)
2 192 33b 2.24 l.21b 9.7 6.8b 149 33 1.45 0.12 41 8
254 17 (7) (7) (7) (6) (6)
(7)
3 188 46b 2.9 1.2' 17.3 10.5b 151 24b 1.83 0.82 43 2b
263 46 (10) (10) (9) (9) (8)
(10)
Values are mean 1 sD; figures in parentheses are numbers of animals.
b P < 0.05 as compared to group 1.
levels of the drug administered for the length of the experiment.
Pilot studies were performed to determine a dose of heparin
which provided protection from glomerular injury. Three ex-
perimental groups were established. Group 1 animals received
USP whole heparin derived from porcine intestinal mucosa (lot
N-5 197, Riker Laboratories Inc., North Ridge, California) at a
dose of 500 USP U/day/kg body wt. Group 2 rats received an
equimolar amount of a low molecular weight fraction of heparin
(lot P-2658, Riker Laboratories Inc.) with an antithrombotic
profile different from the whole heparin used in group I (Table
1). Both the whole USP heparin and the low molecular weight
fraction of heparin were generously provided by Dr. F. J.
Petracek, Riker Laboratories, Inc. The latter was prepared by
high pressure liquid chromatography as previously described
[13]. The isoelectric point of the fraction was determined by
isoelectric focusing [14] using Ampholine PAG plate, pH 3.5 to
9.5 (LKB, Stockholm, Sweden) in an electrofocusing apparatus
(LKB Multiphor). The isoelectric point for the fraction of
heparin was 3.5 to 4.1 which is at the anionic end of the range of
isoelectric point for the whole heparin. Group 3 rats received
either sterile distilled water in a pump or no treatment.
All animals were allowed unlimited access to both water and
rat chow for the next 2 weeks. Each rat was placed in a
metabolic cage the day prior to sacrifice for 24-h collection of
urine. Urine protein was determined using the sulfosalicylic
acid method [15]. Twenty-four hour urine albumin was calculat-
ed using a single radial immunodiffusion technique [161.
On the day of sacrifice the rats were anesthetized with
pentobarbital. The right femoral artery was cannulated with a
PE 50 catheter which was connected to a Statham pressure
transducer. Arterial pressures were recorded with a Gould
physiograph. Heart rate and mean BP were derived from these
recordings. The abdominal cavity was opened, and the animal
was prepared for retrograde perfusion of the left kidney, Blood
taken from the inferior vena cava was used to assess clotting
time, hematocrit, and creatinine. Lee-White clotting time was
measured by the same person throughout the experiments.
Creatinine was determined with a colorimetric method (Creati-
nine 11-Rapid Stat kit, Pierce Chemical Co., Rockville, Illinois).
A small biopsy of the left kidney was taken, placed in a drop
of Tissue-Tek, frozen in liquid nitrogen, and used for immuno-
fluorescence studies. Frozen sections (3 )were cut and rinsed
with phosphate-buffered saline. The sections were overlaid with
fluorescein-conjugated goat anti-rat IgG, 1gM, complement,
albumin, or fibrinogen (Cappel Laboratories, Cochranville,
Pennsylvania). The 1gM was fluoresceinated by the method of
Rinderknecht [17].
The kidney was perfused with 1.5% glutaraldehyde in 0.1 M
phosphate buffer for 5 mm, sliced into ito 2 mm thick slices and
placed in 1.5% glutaraldehyde for overnight fixation. Smaller
pieces of cortex (2 x 2 X 1 mm) were rinsed in buffer, postfixed
in 1% osmium tetroxide, dehydrated through graded alcohols,
and embedded in Araldite. Thick sections (1 j) were cut from
ten blocks in each animal, stained with toluidine blue, and
examined with the light microscope. The number of glomeruli
was recorded for each section. Glomeruli were evaluated for
damage manifested by increased mesangial matrix or cells, and
by formation of blebs or of protein droplets in visceral epithelial
cells. In addition, vessels ranging in size from interlobular
arteries to afferent arterioles were evaluated for permeation of
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fibrinoid or plasma-like material into the vessel wall and for
medial hypertrophy. The percentage of glomeruli and/or vessels
affected by the individual processes described above was then
calculated. Thin sections (60 to 90 m) of representative blocks
from the different groups were cut, stained with uranyl acetate
and lead citrate, and examined in a transmission electron
microscope (JEOL 100S).
All numerical results were expressed as mean I SD. The
nonpaired Student's t test was performed for statistical analy-
sis. P values of less than 0,05 were considered to represent
statistical significance.
Results
In general, group 1 rats that received the whole heparin
appeared healthier than either of the other two groups of rats.
The body weight ratio (body weight at sacrifice divided by body
weight on the day of operation) reflected this inasmuch as group
1 rats maintained their body weight during the 2-week experi-
mental period while groups 2 and 3 rats were reduced to 75 and
70%, respectively, of their original body weight (Table 2). The
clotting time at sacrifice was significantly elevated in group 1
animals receiving whole heparin as compared to the other two
groups. The clotting time for group 2 animals with the heparin
fraction did not differ from the clotting time in controls,
reflecting the lower USP activity of the heparin received by
these animals (Tables 1 and 2). Albumin was undetectable in the
urine of four out of seven whole heparin-treated animals and
markedly reduced in the remaining three rats as compared to
the other two groups. The excretion of albumin in group 2 rats
was considerably decreased when compared to the level of
albumin in the urine of control rats, but this difference did not
attain statistical significance. Mean arterial BP and hematocrit
were significantly decreased in group I rats when compared to
group 3 animals and numerically lower as compared to rats
receiving the fraction of heparin. No evidence of bleeding was
manifest in the heparin-treated animals to account for the
decreased hematocrit. Although statistical significance was not
attained in the analysis of serum creatinine, its numerical value
was lower for the rats which received the whole heparin as
compared to each of the other groups. The animals receiving
the low molecular weight fraction of heparin (group 2) did not
differ significantly from the control rats (group 3) for any of the
physiological studies (Table 2).
Morphological studies. The qualitative alterations in renal
morphology were the same in all groups. Glomerular injury was
both focal and segmental and was of equal severity at all levels
of the cortex. Droplets which stained darkly with toluidine blue
were seen in glomerular and proximal tubule epithelial cells.
Glomerular epithelial cell injury was further manifest by the
formation of blebs with marked attenuation of the epithelial cell
cytoplasm. Mild focal proliferation of both mesangial cells and
matrix was noted (Fig. 1). These features were frequent enough
to allow evaluation of quantitative differences among groups.
The percentage of glomeruli with epithelial blebs and droplets
was significantly lower in group I rats compared to each of the
other groups (Table 3). Increase in mesangium was not evident
in as many glomeruli in group I rats as compared to group 2
rats; this difference attained statistical significance when com-
pared to group 3 rats (Table 3). Occasional capillary lumina
contained a homogeneous substance that resembled the hyalin-
Fig. 1. Light micrograph of a gloinerulus. Note dense protein droplets
and blebs (arrowhead) in epithelial cells. An adhesion of the glomerular
tuft to Bowman's capsule is also present (arrow). (Toluidine blue,
400x)
osis lesion usually associated with focal segmental glomerulo-
sclerosis; adhesions had rarely formed between these lesions
and Bowman's capsule (Fig. 1). Other lumina contained aggre-
gates of platelets (Fig. 2) which occasionally formed thrombi.
Microaneurysms were seen in five of the 1650 glomeruli exam-
ined. None were seen in group I rats. Several mitotic figures
were noted in endothelial cells of glomerular capillaries and
arterioles in each group. The frequency of hyalinosis lesions,
platelet thrombi, microaneurysms, and endothelial mitoses was
too low to submit to statistical analysis.
Alterations were also observed in both arteries and arterioles.
Fibrin was often present in the subendothelial space and/or
within the media. In addition, considerable hypertrophy of the
media was often accompanied by substantial adventitial fibro-
sis. Quantification and statistical analysis of these changes
(Table 3) indicated that group I rats had significantly less fibrin
in vessel walls and a lesser degree of medial hypertrophy as
compared to the vessels in groups 2 and 3 rats. Some tubules
contained hyaline casts while others were dilated. Although
occasional proximal tubule cells had luminal blebs, the brush
border appeared intact for the most part. In the animals with the
most severe glomerular damage, patchy interstitial fibrosis was
noted.
Immunolluorescence microscopy was qualitatively similar in
the three groups. Albumin was present in the droplets in
epithelial cells of glomeruli and proximal tubules. Fibrin was
identified in occasional vessels. IgG and complement were
noted in rare tubular casts, epithelial cell droplets, and in two
glomeruli in mesangial areas. 1gM was consistently negative.
Electron microscopy confirmed and extended the observa-
tions made by light microscopy. Quantitation of ultrastructural
changes was not undertaken. Epithelial droplets and blebs were
noted (Fig. 3). Further evidence of epithelial cell injury was
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Table 3. Comparison of quantitative morphologic differencesa
Group N
Percentage of glomeruli examined with
Arteries and arterioles
.Increase rn
mesangium
Epithelial cell
Blebs Droplets Fibrin Medial hypertrophy
1
2
3
6
7
8
23.8 11.2
36.3 10.2
38.6 12.4b
2.2 4
13 12b
14 7b
9 9
36 lib
22 9b
8 7
32 16b
31 15b
33 25
55 lib
55 13
a All values are mean I si.
b P < 0.05 as compared to group I.
manifest by lifting of the foot processes from the underlying
glomerular basement membrane or mesangial matrix. An in-
crease in mesangial matrix was corroborated by electron mi-
croscopy. Electron dense material in vascular walls had the
characteristic periodicity (225 A) of fibrin. In areas where fibrin
and other plasma proteins had seeped into the vessel wall, the
smooth muscle cells were injured as manifest by intracellular
edema or vesicles. Fibroblasts were the predominant cells in
the thickened adventitia. The luminal surface of many of the
arteriolar endothelial cells had a ruffled irregular appearance
associated with microfilaments with dense bodies in the cyto-
plasm (Fig. 4).
Discussion
Severe renal ablation results in altered glomerular hemody-
namics, proteinuria, progressive glomerular sclerosis, renal
failure, and death [4, 7—9]. Purkerson demonstrated that the
administration of heparin to rats with severe reduction of renal
mass partially prevents this renal injury [7, 10]. Heparin has two
major physiological actions which may contribute to these
protective effects: neutralization of serine proteases and the
enhancement of the negative electric potential of the vascular
wall [11, 12]. Inactivation of the serine proteases including
clotting factors IX, X, XI, and XII produces anticoagulation
[12]. Inhibition of another serine protease, renal kallikrein,
leads to decreased production of renin [18, 19] or to an
alteration in RBF [18] which may result in lower BP or a
reduction in glomerular hyperfiltration, respectively [1, 4]. The
negative electric potential of the vascular wall may be increased
secondary to the binding of heparin, a polyanionic molecule, to
the endothelial surfaces [11, 20].
To determine which of these actions contributes to protection
of the remnant kidney from injury, either whole heparin (group
1) or a fraction of heparin (group 2) was administered in
equimolar doses to rats by continuous intravenous delivery of
the drug. Treatment with whole heparin resulted in elimination
of albuminuria and reduction in BP and injury to the kidney.
The fraction of heparin decreased the degree of albuminuria but
did not reduce the severity of the morphological damage as
compared to untreated controls. These findings indicate that the
fraction of heparin lacks the ability to provide protection from
the effects of reducing renal mass perhaps through its inability
to inhibit serine proteases as is discussed below. Further,
although its anionic charge may reduce albuminuria slightly, it
does not provide protection from other aspects of renal damage
in this model. The primary mechanism of the beneficial effects
of whole heparin is not yet understood. While the results of the
Fig. 2. Light micrograph of glomerulus with platelet aggregates (arrow-
head) within capillary lumina. Also note accumulation of fibrinoid
material (F) in wall of afi'erent arteriole. (Toluidine blue, 400x)
present experiments suggest that anticoagulation must contrib-
ute to the protection afforded by heparin, other factors such as
the reduction in BP and elimination of albuminuria may also be
important.
The clotting profile for the fraction of heparin used in this
study is distinct from the whole heparin as depicted in Table I.
The fraction of heparin has decreased USP anticoagulant activi-
ty but greatly increased antifactor Xa activity as compared to
the whole heparin. Whole heparin binds to antithrombin Ill
producing a change in its conformation and accelerating its
inactivation of the serine proteases, factors IX, X, XI, and XII,
and thrombin [12, 21]. This anticoagulant activity depends on
both the molecular weight [22, 23] and linear charge-density [24]
of heparin. The low molecular weight fractions examined in the
literature (5,000 to 6,000 daltons) probably interfere with factor
Xa independently of antithrombin III and serine proteases by
inhibiting phospholipid binding [25—27]. The clotting time in the
rats receiving the heparin fraction was similar to control rats
and significantly shorter than the clotting time in the rats which
received whole heparin. The inability of the heparin fraction to
produce anticoagulation suggests that it cannot inhibit the
serine proteases of the coagulation cascade. This was further
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Fig. 3. Electron micrograph of portion of a glomerulus. Note numerous protein droplets (D) and focal obliteration of foot processes (F) of epithelial
cells. Also note blebs and attenuation of cytoplasm of epithelial cells (arrowheads). (Uranyl acetate and lead citrate, 4700x)
documented by the similarity of the number of vessels which
had seepage of fibrin into the vascular wall when compared to
control untreated animals. Since the animals treated with the
heparin fraction showed no improvement as compared to
untreated rats, high antifactor Xa activity does not contribute to
the protective effect afforded by heparin.
When coumadin, an anticoagulant which works through a
different mechanism than heparin, was administered to rats
following reduction in renal mass, fewer abnormal glomeruli
were noted although the differences were not statistically
significant [101. Moreover, the analysis of these results was
complicated by the significant lowering of BP with coumadin
therapy [10].
Systemic hypertension is always present following reduction
in renal mass and was documented in the untreated animals by
both indirect and direct BP measurements. Morphologic confir-
mation of its effect in this study was demonstrated by the
fibrinoid necrosis and medial hypertrophy in arterioles and the
increase of microfilaments in association with a ruffled luminal
surface of the arteriolar endothelial cells. The latter has been
previously described in at least two experimental models of
hypertension in rats [28, 29]. Heparin has previously been
shown to reduce BP in rats with renal ablation [7] and in several
experimental models of hypertension [21, 30]. When an antihy-
pertensive regimen was administered to rats with severe reduc-
tion in renal mass, glomerular injury was lessened but not to the
extent observed in the rats treated with heparin in the same
study [7]. The effect of heparin on the renal vasculature was not
studied in those experiments. In the present work, the total
number of vessels with fibrin in the walls was less in whole
heparin-treated rats as one might expect since such lesions are
probably secondary to systemic hypertension. However, some
vessels in whole heparin-treated animals were involved by
"fibrinoid necrosis" as severe as any observed in either of the
other two groups, a finding similar to that observed by Wilson
et al [31] in their heparin-treated stroke prone spontaneously
hypertensive rats. The mechanism whereby heparin decreases
BP is not clear and may occur secondary to the decrease in
hematocrit or to a direct effect of heparin on the renin-
angiotensin system [11]. The former has been discounted in a
study in which it was shown that blood volume was not
decreased in rats treated chronically with heparin [211. Early
support for an effect of heparin on the renin-angiotensin system
is provided by the report that heparin had a natriuretic and
aldosterone suppressing effect [32]. Renal kallikrein, a serine
protease, which may stimulate the renin-angiotensin system
[18], seems to be inhibited by whole heparin; this may result in
lowered BP. The lack of effect on BP by the fraction of heparin
used in this study indicates that it is the higher molecular weight
portion of the whole hepariri which is inhibitory for serine
proteases and which produces this antihypertensive effect as
well as producing anticoagulation. However, since the use of an
antihypertensive regimen by others did not afford complete
protection from the effects of reduction of renal mass [7],
? 
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Fig. 4. Electron micrograph of portion of small artery. Note ruffled surface of endothelial cell with associated microfilaments (F) and dense bodies(D) parallel to the surface of cell. (Uranyl acetate and lead citrate, 43600x)
lowering BP cannot account for the entire beneficial effect of
heparin.
Heparin may also alter intrarenal hemodynamics through its
inhibition of renal kallikrein, a serine protease which interacts
with the renal prostaglandins [18, 19]. Alterations in glomerular
hemodynamics, most notably increased capillary plasma flow
and transcapillary hydraulic pressure, are key factors in the
genesis of the glomerular damage following reduction of renal
mass [4]. The ultimate mediators of the changes in intrarenal
hemodynamics in this model have not been determined. How-
ever, it seems possible that the renal prostaglandins and kinins
play an important role. Thus, the ability of heparin to inhibit
kallikrein may favorably affect intrarenal hemodynamics fol-
lowing reduction of renal mass. In addition, this would be
consistent with the lack of effect observed with the fraction of
heparin used in this study which does not seem capable of
inhibiting serine proteases. However, this mechanism must
remain speculative until the effects of the interactions between
the renal prostaglandin and kinin systems on intrarenal hemo-
dynamics are better defined.
Proteinuria and albuminuria have been constant features
following reduction in renal mass [7—9]. In fact, partial loss of
the charge as well as size-selective barrier to glomerular filtra-
tion is responsible for the increased excretion of protein and
albumin [9]. Heparin is a polyanionic molecule which has been
shown to increase the negative electric potential of the vascular
wall [11, 201. It can be postulated that heparin may restore some
of the lost negative charge of the glomerular capillary wall.
Urinary protein levels decreased only slightly in Purkerson's
work following administration of commercially available hepa-
rin [7]; albumin excretion was not studied. In our experiments
the albuminuria virtually disappeared in the animals treated
with whole heparin and was considerably lower in those ani-
mals which received the anionic low molecular weight fraction
of heparin as compared to control untreated rats. It is possible
that the negative charge of heparin or the fraction of heparin has
contributed to the lessening of albuminuria. However, the lack
of protection from renal injury in the rats receiving the fraction
of heparin would indicate that the anionic nature of heparin
does not contribute in a major way to its overall beneficial effect
in this model.
In conclusion, these experiments confirm the earlier findings
of Purkerson and associates that heparin therapy lessens the
renal injury which would otherwise follow severe reduction of
renal mass, In addition, a low molecular weight fraction of
heparin with a different clotting profile but a similar anionic
nature did not provide such a protective effect. The results
suggest that several actions of heparin in concert provide
protection from injury following reduction in renal mass, in-
cluding: (1) anticoagulation, (2) antihypertensive effect, and
possibly, (3) an effect on glomerular hemodynamics. A defini-
tive explanation of the mechanisms of actions of heparin in this
model awaits further understanding of the control of intrarenal
hemodynamics and the antihypertensive effect of heparin itself.
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